Partnership for Detection of Infection by Category B Pathogens

B 类病原体感染检测合作伙伴关系

基本信息

批准号：
8133376
负责人：
Frances S. Ligler
金额：
$ 75.23万
依托单位：
U.S. NAVAL RESEARCH LABORATORY
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-01 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8133376
关键词：
Address Antibodies Area Automation Biological Assay Biological Markers Biosensing Techniques Brucella Buffers Campylobacter Categories Clinical Code Color Coxiella Cryptosporidium parvum Cytometry Data Detection Development Device or Instrument Development Devices Diagnosis Diagnostic Elements Escherichia coli Exposure to Giardia lamblia Goals Government Hospitals Human Human Resources Immune Infection Infectious Agent Laboratories Laboratory Research Listeria Magnetism Measurement Methodology Methods Microspheres Military Personnel Monitor Nucleic Acids Output Pathogen detection Patients Performance Physicians&apos Offices Physiological Preparation Process Proteins Public Health Q Fever Reagent Research Personnel Robotics Running Salmonella Sampling Screening procedure Sensitivity and Specificity Shigella Site Solid Sorting - Cell Movement System Technology Testing Tracer Training Universities Work assay development base biodefense cost cost effectiveness high throughput screening improved interest microorganism nanoparticle novel pathogen pathogen exposure point of care point-of-care diagnostics rapid technique response user-friendly vaccine efficacy

项目摘要

DESCRIPTION (provided by applicant): The goal of this proposed work is to develop a rapid, automated, multi-analyte diagnostic system based on a novel microflow cytometer for screening exposure to category B pathogens. The resulting device will be portable and field deployable for rapid point-of-care and on-site diagnosis of exposure. The technology can also be used for monitoring efficacy of vaccines as they are developed. Target analytes will include, but are not limited to, Brucella, Coxiella, Salmonella, Campylobacter, E. coli, Shigella, Listeria, Cryptosporidium parvum, Giardia lamblia, and VEE. Development of the proposed diagnostic system will be two pronged, including both assay and device development. First; potential assay formats, using coded microspheres as the solid support, will be investigated, including direct detection of pathogen and indirect identification of pathogen exposure by detecting anti-pathogen antibodies. Optimized assays will be run both in buffer and spiked clinical samples. Candidate capture and tracer reagents, including antibody and non-antibody recognition molecules, will be screened with the goal of reaching physiologically relevant limits-of-detection. Magnetic nanoparticles will be used to pre-concentrate pathogens within the disposable element of the device. Second, expansion of the current microflow cytometry technology will include development and optimization of the 3-color analysis capabilities, automation of the portable system, and inclusion of pathogen sorting capability. The developed system can address of number of the areas of concern for public health including: Assays that demonstrate the highest performance for their detecting pathogens in relevant clinical samples (e.g., sensitivity, specificity, rapidity, ruggedness, ease-of-use and cost-effectiveness). Rapid sample preparation, processing, and target concentration. Improved technologies, methodologies, and reagents for simultaneous testing for multiple targets. Technologies that integrate multiple methods of parallel measurements for detection in the same platform, such as identifying nucleic acids, proteins, and other targets from agents in the same assay. Technologies targeting multiple biomarkers or signature profiles to identify human immune or other physiological responses during infection. Technology adaptable for high throughput, robotic, and automated data output and analyses at minimal cost.

描述（由申请人提供）：这项提出的工作的目的是基于新型的微流动仪，开发快速，自动化的多分析诊断系统，以筛查暴露于B类病原体。最终的设备将是可移植的，并且可部署现场，以快速护理和现场诊断暴露。该技术还可以用于监测疫苗开发的疗效。目标分析物将包括但不限于布鲁氏菌，考克斯氏菌，沙门氏菌，弯曲杆菌，大肠杆菌，志贺氏菌，李斯特菌，加密孢子虫，兰迪亚·兰布利亚和Vee。拟议的诊断系统的开发将是两个方格，包括分析和设备开发。第一的;将研究使用编码的微球作为固体支持的潜在测定格式，包括直接检测病原体和间接鉴定病原体暴露通过检测抗病原体抗体。优化的测定将在缓冲液和尖刺临床样品中进行。将筛选候选捕获和示踪剂试剂，包括抗体和非抗体识别分子，其目的是达到生理相关的检测限制。磁性纳米颗粒将用于在设备的一次性元件内预浓缩病原体。其次，当前微流细胞仪技术的扩展将包括三色分析能力的开发和优化，便携式系统的自动化以及病原体分类能力的包含。开发的系统可以解决公共卫生关注领域的数量，包括：在相关临床样本中检测病原体的最高性能（例如，灵敏度，特异性，速度，坚固性，易用性和成本效益）的测定法。快速样品制备，加工和目标浓度。改进的技术，方法和试剂，用于同时测试多个目标。在同一平台中整合多种并行测量方法以检测的技术，例如在同一测定中鉴定核酸，蛋白质和其他靶标。针对多种生物标志物或签名特征的技术，以鉴定感染过程中人类免疫或其他生理反应。技术适应高通量，机器人和自动化数据输出，并以最低的成本进行分析。

项目成果

期刊论文数量（16）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

A multiwavelength microflow cytometer.

多波长微流式细胞仪。

DOI：
发表时间：
2009
期刊：
NRL review (1988)
影响因子：
0
作者：
Ligler,FrancesS;Erickson,JeffreyS;Golden,JoelP;Kim,JasonS;Nasir,Mansoor;Howell,PeterJ;Thangawng,AbelL;Hilliard,LisaR;Shriver-Lake,LisaC;Anderson,GeorgeP
通讯作者：
Anderson,GeorgeP

Optimization of antibody-conjugated magnetic nanoparticles for target preconcentration and immunoassays.